Recent Updates
Recently added Catalysts
SAVA

Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET

Key Takeaway: AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, August 8th at 8:30 a.m. Eastern Time. Event details fol

Full Press Release Details

AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, August 8th at 8:30 a.m. Eastern Time.
Event details follow:
Date: Thursday, August 8 th
Time: 8:30 a.m. Eastern Time
Audio Webcast: https://www.CassavaSciences.com/company-presentations
Or
Audio Webcast: https://edge.media-server.com/mmc/p/zjvmjjcr
A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences’ website for 90 days following the webcast.
About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450 or ESchoen@CassavaSciences.com
Last updated: Aug 1, 2024